EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Identa Corp (IDTA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Identa Corp $0.52, price $0.31, upside +67.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US4516712001

IC Identa Corp logo Thin data Sep 23, 2026

Identa Corp

IDTA · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $0.5200 · Strongly undervalued (+68%)
!Quality 53/100
!Weak Growth (revenue 5y −1.4 %/yr)
✓Solidly profitable · 11.3% net margin (TTM)
✓Moderate debt · generates free cash flow
✓Ranks above peers (10/13)
✓Wide moat 66/100
!Evidence only low, so the estimate is less certain

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.70 $0.1000 Fair Value $0.5200 Jul 2017 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.1000 – $2.70 · fair‑value band $0.2700 – $0.6700 · the $0.3100 price screens below the $0.5200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Identa in your weekly email

Every Wednesday you see whether Identa is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

IDenta Corp. operates as a detection and forensic science company. The company offers drug, and explosives testing kits; aero chamber sniffer; forensic; and urine, and saliva drug testing products.

Show more

IDenta Corp. operates as a detection and forensic science company. The company offers drug, and explosives testing kits; aero chamber sniffer; forensic; and urine, and saliva drug testing products. It provides its solutions to law enforcement, military, and government agencies, as well as other organizations that deal in fighting illicit drugs and terrorist threats. The company has operations in Israel, the United States, the United Nations, DEA, Germany, France, Italy, Spain, Indonesia, Brazil, Mexico, South Africa, Australia, Canada, and internationally. IDenta Corp. was founded in 2002 and is headquartered in Jerusalem, Israel.

Stock analysis

Identa Corp (IDTA) currently trades at $0.3100, while our model-based Fair Value estimate is $0.5200, implying the stock looks roughly 40.4% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $0.5400 per share, and 18 of the 24 models we run sit above the $0.3100 price.

Bear case: the Asset-Based group reads lowest at $0.1500, and 6 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.2700 (bear) to $0.6700 (bull), the price of $0.3100 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Identa Corp reported revenue of $1.4M in FY2025 versus $1.4M in FY2021, a compound −0.7%/yr. Reported net income was $99.0K in FY2025, compounding +9.4%/yr from FY2021.

Key figures

Market cap $1.3M · P/E ratio 7.8 · P/S ratio 0.57 · EPS (TTM) $0.0400 · Net margin 7.3% · Return on equity 23.5% · Return on assets (EBIT) 10.6% · Operating margin 18.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 105% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 68%, IDTA screens cheaper than that median.

Fair Value models

Bear $0.2700 Fair Value $0.5200 Bull $0.6700
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0294 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.1200 $0.2100 $0.3600 78
Growth DCF $0.1200 $0.2100 $0.3400 76
Owner Earnings $0.2900 $0.5000 $0.8300 74
All 24 models by family
DCF Models
FCF DCF $0.1200 $0.2100 $0.3600 78
Owner Earnings $0.2900 $0.5000 $0.8300 74
5Y Revenue Exit $0.2900 $0.5600 $0.9200 70
5Y EBITDA Exit $0.3400 $0.6500 $1.04 73
5Y P/E Exit $0.2700 $0.5100 $0.7800 69
10Y Revenue Exit $0.2100 $0.4400 $0.7800 64
10Y EBITDA Exit $0.2600 $0.5100 $0.8800 66
10Y P/E Exit $0.2100 $0.4100 $0.6700 62
Earnings-Based
Graham-Dodd $0.1700 $0.6600 $0.9000 64
Lynch FV $0.1600 $0.2300 $0.3100 61
PEG = 1.0 $0.1600 $0.2300 $0.3100 57
EPV $0.3500 $0.4100 $0.4600 74
Multiples
P/E Multiple $0.4000 $0.5400 $0.6700 63
P/S Multiple $0.3100 $0.4200 $0.5200 58
P/B Multiple $0.3100 $0.4200 $0.5200 55
EV/EBIT $0.5600 $0.7600 $0.9500 66
EV/EBITDA $0.5100 $0.6800 $0.8600 67
EV/Revenue $0.3900 $0.5700 $0.7500 53
Asset-Based
NCAV (Graham) $0.1100 $0.1500 $0.2200 54
Growth DCF
Growth DCF $0.1200 $0.2100 $0.3400 76
Rev-Margin DCF $0.2900 $0.5500 $0.8600 71
Economic Profit
Residual Income $0.1900 $0.2200 $0.3900 68
ROIC Compounder $0.3900 $0.5100 $0.6700 72
Growth Earnings
Growth-Adj P/E $0.3000 $0.4300 $0.5500 68

Open the full fair value analysis →

Notify me when IDTA reaches fair value

Put IDTA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 50 · Market factors (momentum, volatility) 56

Profitability 48
Margins and returns on capital today
Quality Growth 28
Are margins and returns improving?
Cashflow 29
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 57
Disciplined investing over empire-building
Low Volatility 44
Calm price path (market factor)
Momentum 56
Price trend over the last 3–12 months (market factor)
52W Momentum 72
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Start year 2020 (pandemic). Over 10 years: +6.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−2.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 14%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +19.3% a year for the price.

Watch IDTA, get fair value alerts →

Compare Identa Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside +68% · Top 25%
Profitability
Return on equity (TTM) 23% · Top 25%
Return on assets 13% · Top 25%
Net margin (TTM) 11% · Above median
Operating margin (TTM) 18% · Top 25%
Growth and dividend
Revenue growth 198% · Top 25%
Balance sheet
Debt / equity 0.53× · Highest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 7.8× · Cheapest 25%
P/B 1.43× · Cheaper than median
P/S (TTM) 0.74× · Cheapest 25%
P/FCF 31.1× · Priciest 25%
EV/EBITDA 3.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)94 · sector 8
HEALTH (low debt)73 · sector 95
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $658.52 $682.58 +4%
Danaher Corporation DHR $221.09 $207.76 −6%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 562.80 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $521.50 $495.84 −5%
Agilent Technologies, Inc A $167.26 $63.90 −62%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $247.46 $272.21 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Identa Corp Fair Value". https://www.fairvalue-calculator.com/stock/IDTA

Frequently asked questions

Is Identa Corp (IDTA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.5200 versus a price of $0.3100, about +68% upside (undervalued).
What is the fair value of IDTA?
Our model-based fair value for Identa Corp is $0.5200 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.3100.
What is the quality score of IDTA?
Identa Corp has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Identa Corp (IDTA)?
Our model-based price target is the fair value of $0.5200 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario $0.2700, optimistic scenario $0.6700. It is a calculation from audited fundamentals, not an analyst target.
What is the Identa Corp stock forecast for 2026?
Our models put fair value at $0.5200, about +68% upside versus a price of $0.3100 (undervalued). Cautious scenario $0.2700, optimistic scenario $0.6700. The calculation is refreshed regularly with new filings.
What is the revenue of Identa Corp (IDTA)?
Identa Corp reported trailing-twelve-month revenue of about $1.7M (latest available figure, as of Sep 23, 2026).
What growth is priced into Identa Corp (IDTA)?
For today's price to be fair in a discounted-cash-flow model, Identa Corp would have to grow free cash flow by +22.2 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.4 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of IDTA use?
Our models discount Identa Corp at 8.9 %: a base by market capitalisation (nano), damped by beta 0.67, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Identa Corp that is +22.2 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Identa Corp (IDTA) delivered so far?
Over the past 5 years revenue at Identa Corp grew -1.4 % a year. The price currently implies +22.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Identa Corp (IDTA) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Identa Corp (+22.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Identa Corp (IDTA)?
The free-cash-flow yield on the price is 3.21 %: that much free cash flow Identa Corp produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Identa Corp (IDTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Identa Corp it is $0.5200 per share (as of Sep 23, 2026), against a price of $0.3100. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Identa Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, IDTA trades below its calculated fair value: price $0.3100, fair value $0.5200, a gap of about +68% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDTA?
No. The price is what the market pays today ($0.3100); the fair value is what the company's own numbers justify ($0.5200). For Identa Corp the two are $0.2100 per share apart. That gap is exactly why we show both numbers side by side.
How much is Identa Corp worth?
The market values Identa Corp at about $1.3M (market capitalisation, as of Sep 23, 2026). Per share that is $0.3100; our models calculate a fair value of $0.5200 per share.
What do the bullish and bearish scenarios say about IDTA?
Our models span a range for Identa Corp: cautious scenario $0.2700, base $0.5200, optimistic $0.6700 per share (as of Sep 23, 2026, price $0.3100). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of IDTA?
Identa Corp trades at a price-to-earnings ratio of 7.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.5200 is built from several models across several years. Other multiples: P/B 1.4, P/S 0.7, EV/EBITDA 3.4.
How solid is the balance sheet of Identa Corp (IDTA)?
Balance-sheet figures for Identa Corp (as of Sep 23, 2026): return on equity 23.5%, debt of 0.53 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is IDTA from its 52-week high?
Identa Corp trades at $0.3100, about 13% below its 52-week high of $0.3560 and 105% above the low of $0.1510 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5200 is for.
Which stocks are comparable to Identa Corp?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Identa Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.3100, calculated fair value $0.5200 (+68%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IDTA calculated?
We run Identa Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Identa Corp currently trades 68 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Identa Corp (IDTA)?
The closing price on Sep 23, 2026 was $0.3100. Our model-based fair value is $0.5200, about +68% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Identa Corp right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($0.2700 to $0.6700) leaves room in how you read the outcome.

Key figures of Identa Corp

How large is the market capitalisation of Identa Corp (IDTA)?
The market capitalisation of Identa Corp is $1.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Identa Corp (IDTA)?
The price-to-sales ratio of Identa Corp is 0.57 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Identa Corp (IDTA)?
Earnings per share at Identa Corp are $0.0400 (price ÷ EPS = P/E 7.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Identa Corp (IDTA)?
The net margin of Identa Corp is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Identa Corp (IDTA)?
The return on equity (ROE) of Identa Corp is 23.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Identa Corp (IDTA)?
On an EBIT basis the return on assets of Identa Corp is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Identa Corp (IDTA)?
The operating margin of Identa Corp is 18.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Identa Corp (IDTA)?
Revenue at Identa Corp is growing +198% versus a year earlier (3y avg −2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Identa Corp (IDTA)?
Earnings per share at Identa Corp are growing −1.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Identa Corp (IDTA) carry?
The net debt of Identa Corp is $89.9K (fiscal year 2025, ≈ 2.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Identa Corp in the live analysis

One click puts Identa Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.